OSUR

Business Context and Reporting Period

Company: OraSure Technologies, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2006
Business Overview: The company develops, manufactures, and markets oral specimen collection devices, diagnostic products (including in vitro diagnostic tests), and medical devices for cryosurgery. Key products include the OraQuick ADVANCE rapid HIV test, Intercept oral fluid drug testing systems, and Histofreezer cryosurgical devices.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Total revenues decreased 1% year-over-year to $32.8 million. This was driven by a 41% decline in insurance risk assessment sales and an 8% decline in cryosurgical systems sales, partially offset by growth in infectious disease (8%) and substance abuse testing (16%).
• Net Income Decrease: Net income fell 30% to $2.1 million. The decline is primarily attributed to a $1.8 million pre-tax charge for stock-based compensation (due to the adoption of SFAS No. 123R) and a $1.8 million income tax provision, neither of which were recorded in the prior year.
• Improved Margins: Gross margin improved to 63% from 57% in the prior year, aided by the absence of a $1.5 million asset charge recorded in 2005.
• Debt Increase: Long-term debt increased significantly due to a $10 million borrowing in June 2006 to purchase two previously leased facilities in Bethlehem, Pennsylvania.
• Customer Concentration: Prestige Brands Holdings' share of revenue dropped from 21% to 12% for the six-month period, while Abbott Laboratories' share increased from 5% to 9%.

Guidance, Outlook, and Risks

• Outlook: Management expects full-year 2006 revenues in the insurance risk assessment market to decline approximately $1.0 million below 2005 levels. Sales to Prestige for 2006 are projected to be less than 50% of 2005 levels due to competition and inventory reduction. Conversely, sales to SSL International in Europe are expected to increase, potentially ranging from 30% to 130% over 2005 levels.
• Regulatory & Product: The company is pursuing CE marking for the OraQuick ADVANCE product to enable European sales. It expects to launch the product in Europe following country-specific registrations.
• Stock-Based Compensation: The adoption of SFAS No. 123R resulted in significant non-cash expenses. Unrecognized compensation expense related to unvested options and restricted stock totals over $11 million as of June 30, 2006.
• Legal Contingencies: The company is engaged in patent infringement litigation against Schering-Plough regarding cryosurgical wart removal products. A trial schedule is pending.
• Liquidity Covenants: The amended credit facility requires a minimum liquidity of $25 million, with at least $15 million held by Comerica or its affiliates. The company was in full compliance as of June 30, 2006.

Investor Verification Checklist

• Stock Compensation Impact: Verify the sustainability of net income given the one-time nature of the SFAS 123R adoption charge versus recurring stock-based compensation expenses.
• Prestige Distribution Performance: Monitor the continued decline in sales to Prestige Brands Holdings and the company's ability to offset this with international sales via SSL International.
• Government Bulk Orders: Assess reliance on bulk purchase orders from the CDC and SAMHSA for OraQuick ADVANCE, as delays or reductions could materially impact revenue.
• Debt Service: Review the impact of the new $10 million debt on future interest expenses and cash flow, noting the first principal repayment of $250,000 is due in December 2006.
• Regulatory Approvals: Track the timeline for CE marking approval for OraQuick ADVANCE, which is critical for the planned European expansion.